[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmzLy0MvxrI-pGkw1NZhpG970bSlYtAlOy5UEfWyMlfI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":69,"rows":76},"United Therapeutics",[4],83,false,8,31,14677,6,3,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Pulmonary Arterial Hypertension",39,{"name":18,"count":19},"Pulmonary Hypertension",22,{"name":21,"count":8},"Interstitial Lung Disease",{"name":23,"count":24},"Hypertension, Pulmonary",7,{"name":26,"count":27},"PAH",5,{"name":29,"count":12},"Hypertension",{"name":31,"count":12},"Familial Primary Pulmonary Hypertension",{"name":33,"count":12},"Vascular Diseases",[35,40,45,50,55,59,64],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05203510","A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension","2026-04-30","Parenteral Treprostinil",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04905693","Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease","2026-06","Inhaled Treprostinil",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03683186","A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension","2026-12","Ralinepag",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03045029","ADAPT - A Patient Registry of the Real-world Use of Orenitram®","2027-03","Oral treprostinil",{"nctId":56,"briefTitle":57,"date":58,"intervention":44},"NCT05943535","Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","2027-11",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06878560","Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD","2028-10","10 GE Xenokidney",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07224763","Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD","2029-03","GGTA1 KO Thymokidney",[70,71,72,73,74,75],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[77,188,206,321,373,396,416,473,515,539,563,586,604,626,720,774,822,854,887,911,929,947,973,997,1020,1048,1066,1084,1110,1138,1156,1174,1192,1210,1235,1253,1271,1293,1311,1337,1355,1378,1400,1424,1449,1467,1508,1534,1560,1578,1596,1614,1632,1655],{"intervention":78,"totalTrials":79,"cells":80},"Oral Treprostinil",10,{"EARLY_PHASE1":81,"PHASE1":84,"PHASE2":86,"PHASE3":119,"PHASE4":169,"NA":180},{"trials":82,"activeCount":83},[],0,{"trials":85,"activeCount":83},[],{"trials":87,"activeCount":83},[88,99,110],{"nctId":89,"briefTitle":90,"status":91,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":83,"conditions":96,"interventions":98},"NCT02603068","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis","WITHDRAWN",[72],"2018-04","2018-07","2016-02",[18,97],"Pulmonary Fibrosis",[54],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT02276872","Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years","COMPLETED",[72],"2017-07-20","2014-12-18",32,[26],[109],"oral treprostinil",{"nctId":111,"briefTitle":112,"status":91,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":83,"conditions":116,"interventions":117},"NCT03016468","Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH",[72],"2018-09","2017-05",[15],[118,78],"Parenteral Remodulin (treprostinil)",{"trials":120,"activeCount":83},[121,132,141,151,161],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"NCT03043651","Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF","TERMINATED",[73],"2020-03-02","2018-01-30",48,[130],"Pulmonary Hypertension Associated With HFpEF",[54],{"nctId":133,"briefTitle":134,"status":102,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},"NCT01027949","An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension",[73],"2020-02-12","2007-01-16",894,[15],[78],{"nctId":142,"briefTitle":143,"status":91,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":83,"conditions":148,"interventions":150},"NCT03055234","Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)",[73],"2021-12","2022-12","2017-06",[149],"Pulmonary Hypertension Associated With Sickle Cell Disease",[78],{"nctId":152,"briefTitle":153,"status":124,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT03037580","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction",[73],"2019-12-03","2017-08-15",84,[18,159],"Heart Failure With Preserved Ejection Fraction",[54],{"nctId":162,"briefTitle":163,"status":91,"phases":164,"primaryCompletion":145,"completion":165,"start":166,"enrollment":83,"conditions":167,"interventions":168},"NCT02999906","Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension",[73],"2022-06","2017-10",[15],[78],{"trials":170,"activeCount":179,"soonestReadout":38},[171],{"nctId":36,"briefTitle":37,"status":172,"phases":173,"primaryCompletion":38,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"ACTIVE_NOT_RECRUITING",[74],"2028-04-30","2022-10-20",52,[15],[39,78],1,{"trials":181,"activeCount":179,"soonestReadout":53},[182],{"nctId":51,"briefTitle":52,"status":172,"phases":183,"primaryCompletion":53,"completion":53,"start":184,"enrollment":185,"conditions":186,"interventions":187},[],"2017-07-18",300,[15],[54],{"intervention":39,"totalTrials":179,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":204},{"trials":191,"activeCount":83},[],{"trials":193,"activeCount":83},[],{"trials":195,"activeCount":83},[],{"trials":197,"activeCount":83},[],{"trials":199,"activeCount":179,"soonestReadout":38},[200],{"nctId":36,"briefTitle":37,"status":172,"phases":201,"primaryCompletion":38,"completion":174,"start":175,"enrollment":176,"conditions":202,"interventions":203},[74],[15],[39,78],{"trials":205,"activeCount":83},[],{"intervention":44,"totalTrials":207,"cells":208},11,{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":224,"PHASE4":307,"NA":319},{"trials":210,"activeCount":83},[],{"trials":212,"activeCount":83},[],{"trials":214,"activeCount":83},[215],{"nctId":216,"briefTitle":217,"status":91,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":83,"conditions":221,"interventions":223},"NCT03012646","Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD",[72],"2019-04","2017-04",[18,222],"Chronic Obstructive Pulmonary Disease",[44],{"trials":225,"activeCount":306,"soonestReadout":43},[226,236,246,254,263,271,281,288,297],{"nctId":227,"briefTitle":228,"status":102,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT04708782","Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis",[73],"2026-02-02","2021-06-01",598,[234,21],"Idiopathic Pulmonary Fibrosis",[44],{"nctId":237,"briefTitle":238,"status":91,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":83,"conditions":243,"interventions":244},"NCT01557647","Safety and Efficacy of Inhaled Treprostinil in Patients With PAH",[73],"2015-12","2016-06","2012-06",[15],[245],"Inhaled treprostinil",{"nctId":247,"briefTitle":248,"status":91,"phases":249,"primaryCompletion":250,"completion":250,"start":242,"enrollment":83,"conditions":251,"interventions":252},"NCT01557660","Inhaled Treprostinil for PAH: Open-label Extension",[73],"2018-12",[15],[253],"inhaled treprostinil",{"nctId":255,"briefTitle":256,"status":102,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT05255991","Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis",[73],"2025-06-30","2022-10-04",597,[234,21],[44],{"nctId":41,"briefTitle":42,"status":264,"phases":265,"primaryCompletion":43,"completion":43,"start":266,"enrollment":267,"conditions":268,"interventions":270},"ENROLLING_BY_INVITATION",[73],"2022-09-06",1850,[234,21,269],"Progressive Pulmonary Fibrosis",[44],{"nctId":272,"briefTitle":273,"status":124,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT02633293","An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE",[72,73],"2021-08-01","2016-09-15",243,[18,21,279],"Combined Pulmonary Fibrosis and Emphysema",[44],{"nctId":56,"briefTitle":57,"status":282,"phases":283,"primaryCompletion":58,"completion":58,"start":284,"enrollment":285,"conditions":286,"interventions":287},"RECRUITING",[73],"2023-10-30",698,[269,21],[44],{"nctId":289,"briefTitle":290,"status":102,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT02630316","Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE",[72,73],"2019-12-26","2017-02-03",326,[18,21,279],[44],{"nctId":298,"briefTitle":299,"status":102,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":305},"NCT00147199","Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)",[73],"2007-10","2005-06",235,[18],[245],2,{"trials":308,"activeCount":83},[309],{"nctId":310,"briefTitle":311,"status":102,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT00741819","Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects",[74],"2010-03","2010-12","2008-09",73,[15],[245],{"trials":320,"activeCount":83},[],{"intervention":49,"totalTrials":322,"cells":323},4,{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":339,"PHASE4":369,"NA":371},{"trials":325,"activeCount":83},[],{"trials":327,"activeCount":83},[],{"trials":329,"activeCount":83},[330],{"nctId":331,"briefTitle":332,"status":102,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT02279745","Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension",[72],"2021-03-29","2015-07-08",45,[15],[49],{"trials":340,"activeCount":179,"soonestReadout":48},[341,353,363],{"nctId":342,"briefTitle":343,"status":124,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":79,"conditions":347,"interventions":352},"NCT04084678","A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH",[73],"2023-04-12","2021-01-20",[26,18,29,348,31,33,349,23,350,351,15],"Connective Tissue Disease","Cardiovascular Diseases","Lung Diseases","Respiratory Tract Disease",[49],{"nctId":354,"briefTitle":355,"status":102,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT03626688","A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients",[73],"2025-12-31","2018-08-30",687,[26,18,15,29,361,31,33,349,23,350,351],"Connective Tissue Diseases",[49],{"nctId":46,"briefTitle":47,"status":264,"phases":364,"primaryCompletion":48,"completion":48,"start":365,"enrollment":366,"conditions":367,"interventions":368},[73],"2019-09-23",1000,[26,18,15,29,361,31,33,349,23,350,351],[49],{"trials":370,"activeCount":83},[],{"trials":372,"activeCount":83},[],{"intervention":68,"totalTrials":179,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":376,"activeCount":83},[],{"trials":378,"activeCount":83},[],{"trials":380,"activeCount":179,"soonestReadout":67},[381],{"nctId":65,"briefTitle":66,"status":282,"phases":382,"primaryCompletion":67,"completion":383,"start":43,"enrollment":384,"conditions":385,"interventions":389},[71,72],"2076-03",50,[386,387,388],"ESRD (End-Stage Renal Disease)","Kidney Transplantation","Xenotransplantation",[68],{"trials":391,"activeCount":83},[],{"trials":393,"activeCount":83},[],{"trials":395,"activeCount":83},[],{"intervention":63,"totalTrials":179,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":399,"activeCount":83},[],{"trials":401,"activeCount":83},[],{"trials":403,"activeCount":179,"soonestReadout":62},[404],{"nctId":60,"briefTitle":61,"status":282,"phases":405,"primaryCompletion":62,"completion":406,"start":407,"enrollment":384,"conditions":408,"interventions":409},[71,72],"2075-10","2025-10-29",[386,387,388],[63],{"trials":411,"activeCount":83},[],{"trials":413,"activeCount":83},[],{"trials":415,"activeCount":83},[],{"intervention":417,"totalTrials":27,"cells":418},"treprostinil sodium",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":436,"NA":471},{"trials":420,"activeCount":83},[],{"trials":422,"activeCount":83},[],{"trials":424,"activeCount":83},[],{"trials":426,"activeCount":83},[427],{"nctId":428,"briefTitle":429,"status":91,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":83,"conditions":433,"interventions":435},"NCT01884038","Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients",[72,73],"2010-06","2008-06",[434],"Liver Transplant",[417],{"trials":437,"activeCount":83},[438,446,454,462],{"nctId":439,"briefTitle":440,"status":102,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":16,"conditions":444,"interventions":445},"NCT00058929","A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension",[74],"2005-08","2002-10",[15,18],[417],{"nctId":447,"briefTitle":448,"status":124,"phases":449,"completion":450,"start":451,"enrollment":79,"conditions":452,"interventions":453},"NCT00458042","Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction",[74],"2007-11","2007-03",[23],[417],{"nctId":455,"briefTitle":456,"status":102,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":79,"conditions":460,"interventions":461},"NCT00373360","Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin",[74],"2008-01","2006-09",[18],[417],{"nctId":463,"briefTitle":464,"status":124,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":24,"conditions":469,"interventions":470},"NCT00643604","Rapid Switch From Flolan to Remodulin in the Outpatient Clinic",[74],"2010-01","2012-02","2008-03",[23],[417],{"trials":472,"activeCount":83},[],{"intervention":474,"totalTrials":12,"cells":475},"Remodulin",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":495,"NA":513},{"trials":477,"activeCount":83},[],{"trials":479,"activeCount":83},[],{"trials":481,"activeCount":83},[],{"trials":483,"activeCount":83},[484],{"nctId":485,"briefTitle":486,"status":124,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT00067041","Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft",[72,73],"2003-12","2003-03",30,[492],"Peripheral Vascular Disease",[494],"Remodulin (treprostinil sodium)",{"trials":496,"activeCount":83},[497,505],{"nctId":498,"briefTitle":499,"status":124,"phases":500,"primaryCompletion":501,"completion":501,"start":502,"enrollment":336,"conditions":503,"interventions":504},"NCT00494533","Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension",[74],"2005-10","2005-03",[15],[474],{"nctId":506,"briefTitle":507,"status":102,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":16,"conditions":511,"interventions":512},"NCT02847260","Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)",[74],"2014-03","2012-04",[15],[474],{"trials":514,"activeCount":83},[],{"intervention":516,"totalTrials":179,"cells":517},"Intravenous Treprostinil",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":537},{"trials":519,"activeCount":83},[],{"trials":521,"activeCount":83},[],{"trials":523,"activeCount":83},[],{"trials":525,"activeCount":83},[],{"trials":527,"activeCount":83},[528],{"nctId":529,"briefTitle":530,"status":102,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT03055221","TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)",[74],"2014-02-25","2005-06-10",20,[15],[516],{"trials":538,"activeCount":83},[],{"intervention":540,"totalTrials":179,"cells":541},"Intravenous\u002FSubcutaneous Treprostinil; Oral Treprostinil",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":561},{"trials":543,"activeCount":83},[],{"trials":545,"activeCount":83},[],{"trials":547,"activeCount":83},[],{"trials":549,"activeCount":83},[],{"trials":551,"activeCount":83},[552],{"nctId":553,"briefTitle":554,"status":102,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT03497689","EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension",[74],"2022-05-11","2019-01-31",36,[15],[540],{"trials":562,"activeCount":83},[],{"intervention":564,"totalTrials":179,"cells":565},"Slow Dose Titration Group of Subcutaneous Treprostinil",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":584},{"trials":567,"activeCount":83},[],{"trials":569,"activeCount":83},[],{"trials":571,"activeCount":83},[],{"trials":573,"activeCount":83},[],{"trials":575,"activeCount":83},[576],{"nctId":577,"briefTitle":578,"status":91,"phases":579,"primaryCompletion":93,"completion":93,"start":580,"enrollment":83,"conditions":581,"interventions":582},"NCT02893995","Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension",[74],"2017-02",[15],[564,583],"Rapid Dose Titration Group of Subcutaneous Treprostinil",{"trials":585,"activeCount":83},[],{"intervention":583,"totalTrials":179,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":602},{"trials":589,"activeCount":83},[],{"trials":591,"activeCount":83},[],{"trials":593,"activeCount":83},[],{"trials":595,"activeCount":83},[],{"trials":597,"activeCount":83},[598],{"nctId":577,"briefTitle":578,"status":91,"phases":599,"primaryCompletion":93,"completion":93,"start":580,"enrollment":83,"conditions":600,"interventions":601},[74],[15],[564,583],{"trials":603,"activeCount":83},[],{"intervention":605,"totalTrials":179,"cells":606},"Subcutaneous Treprostinil",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":624},{"trials":608,"activeCount":83},[],{"trials":610,"activeCount":83},[],{"trials":612,"activeCount":83},[],{"trials":614,"activeCount":83},[],{"trials":616,"activeCount":83},[617],{"nctId":618,"briefTitle":619,"status":91,"phases":620,"primaryCompletion":621,"completion":621,"start":147,"enrollment":83,"conditions":622,"interventions":623},"NCT02882126","An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension",[74],"2021-06",[15],[605],{"trials":625,"activeCount":83},[],{"intervention":627,"totalTrials":628,"cells":629},"treprostinil diethanolamine",9,{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":683,"PHASE3":704,"PHASE4":716,"NA":718},{"trials":631,"activeCount":83},[],{"trials":633,"activeCount":83},[634,644,652,659,666,673],{"nctId":635,"briefTitle":636,"status":102,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":490,"conditions":640,"interventions":641},"NCT00963027","Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil",[71],"2009-10","2009-09",[23,15],[642,643],"Treprostinil diethanolamine","Esomeprazole",{"nctId":645,"briefTitle":646,"status":102,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":558,"conditions":650,"interventions":651},"NCT01153386","Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine",[71],"2010-08","2010-07",[15],[642],{"nctId":653,"briefTitle":654,"status":102,"phases":655,"primaryCompletion":656,"completion":656,"start":639,"enrollment":106,"conditions":657,"interventions":658},"NCT00963001","Effect of Food on the Pharmacokinetics of Oral Treprostinil",[71],"2009-11",[23,15],[642],{"nctId":660,"briefTitle":661,"status":102,"phases":662,"primaryCompletion":648,"completion":648,"start":649,"enrollment":663,"conditions":664,"interventions":665},"NCT01165476","Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities",[71],64,[15],[642],{"nctId":667,"briefTitle":668,"status":102,"phases":669,"primaryCompletion":648,"start":648,"enrollment":670,"conditions":671,"interventions":672},"NCT01172496","A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers",[71],24,[15],[627],{"nctId":674,"briefTitle":675,"status":102,"phases":676,"primaryCompletion":466,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":682},"NCT00848939","Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis",[71],"2010-04","2008-12",28,[681],"Systemic Sclerosis",[627,627],{"trials":684,"activeCount":83},[685,693],{"nctId":686,"briefTitle":687,"status":124,"phases":688,"primaryCompletion":689,"completion":689,"start":639,"enrollment":690,"conditions":691,"interventions":692},"NCT00848107","Open-Label Study of Oral Treprostinil in Digital Ulcers",[72],"2011-09",115,[681],[627],{"nctId":694,"briefTitle":695,"status":102,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT00775463","Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine",[72],"2011-03","2011-07","2009-05",148,[681,702],"Scleroderma",[627],{"trials":705,"activeCount":83},[706],{"nctId":707,"briefTitle":708,"status":102,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":714},"NCT01934582","A Pharmacokinetic Substudy of the TDE-PH-304 Protocol",[73],"2013-11","2013-08",13,[15],[715,627],"UT-15C SR",{"trials":717,"activeCount":83},[],{"trials":719,"activeCount":83},[],{"intervention":715,"totalTrials":27,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":736,"PHASE3":756,"PHASE4":770,"NA":772},{"trials":723,"activeCount":83},[],{"trials":725,"activeCount":83},[726],{"nctId":727,"briefTitle":728,"status":102,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT01131845","The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil",[71],"2010-09","2010-05",16,[15,734],"Renal Dysfunction",[715],{"trials":737,"activeCount":83},[738,747],{"nctId":739,"briefTitle":740,"status":102,"phases":741,"primaryCompletion":710,"completion":710,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT01477333","Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®",[72],"2011-10",18,[15],[715,746],"Tyvaso Inhalation Solution",{"nctId":748,"briefTitle":749,"status":102,"phases":750,"primaryCompletion":751,"completion":752,"start":510,"enrollment":753,"conditions":754,"interventions":755},"NCT01588405","Remodulin® to Oral Treprostinil Transition",[72],"2014-07","2014-12",33,[15],[715],{"trials":757,"activeCount":83},[758,762],{"nctId":707,"briefTitle":708,"status":102,"phases":759,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":760,"interventions":761},[73],[15],[715,627],{"nctId":763,"briefTitle":764,"status":102,"phases":765,"primaryCompletion":698,"completion":698,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT00887978","Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension",[73],"2009-06",310,[18],[715],{"trials":771,"activeCount":83},[],{"trials":773,"activeCount":83},[],{"intervention":775,"totalTrials":322,"cells":776},"UT-15C",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":798,"PHASE3":807,"PHASE4":818,"NA":820},{"trials":778,"activeCount":83},[],{"trials":780,"activeCount":83},[781,790],{"nctId":782,"briefTitle":783,"status":102,"phases":784,"primaryCompletion":785,"completion":752,"start":786,"enrollment":106,"conditions":787,"interventions":789},"NCT02318758","Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers",[71],"2014-10","2014-09",[788],"Healthy",[775],{"nctId":791,"briefTitle":792,"status":102,"phases":793,"primaryCompletion":794,"completion":794,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT01746485","Three Times Daily Dosing of UT-15C",[71],"2012-07",19,[788],[775],{"trials":799,"activeCount":83},[800],{"nctId":801,"briefTitle":802,"status":102,"phases":803,"primaryCompletion":804,"completion":804,"start":677,"enrollment":384,"conditions":805,"interventions":806},"NCT01104870","A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension",[72],"2013-01",[18],[775],{"trials":808,"activeCount":83},[809],{"nctId":810,"briefTitle":811,"status":102,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT01560637","An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension",[73],"2021-08-12","2013-09-11",471,[15],[775],{"trials":819,"activeCount":83},[],{"trials":821,"activeCount":83},[],{"intervention":823,"totalTrials":306,"cells":824},"Oral treprostinil (UT-15C) Sustained Release",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":850,"NA":852},{"trials":826,"activeCount":83},[],{"trials":828,"activeCount":83},[],{"trials":830,"activeCount":83},[],{"trials":832,"activeCount":83},[833,842],{"nctId":834,"briefTitle":835,"status":102,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT00325403","FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)",[73],"2011-04","2006-10",349,[18],[823],{"nctId":843,"briefTitle":844,"status":102,"phases":845,"primaryCompletion":315,"completion":314,"start":838,"enrollment":846,"conditions":847,"interventions":848},"NCT00325442","FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and\u002For a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)",[73],354,[18],[849],"Oral treprostinil (UT-15C) sustained release",{"trials":851,"activeCount":83},[],{"trials":853,"activeCount":83},[],{"intervention":855,"totalTrials":306,"cells":856},"Inhaled treprostinil solution",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":883,"NA":885},{"trials":858,"activeCount":83},[],{"trials":860,"activeCount":83},[],{"trials":862,"activeCount":83},[],{"trials":864,"activeCount":83},[865,874],{"nctId":866,"briefTitle":867,"status":124,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT03794583","Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)",[73],"2022-11-29","2018-12-21",41,[18,222],[855],{"nctId":875,"briefTitle":876,"status":124,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":882},"NCT03496623","A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)",[73],"2022-10-13","2018-05-08",188,[18,222],[855],{"trials":884,"activeCount":83},[],{"trials":886,"activeCount":83},[],{"intervention":888,"totalTrials":179,"cells":889},"UT-15C 1 mg",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":907,"NA":909},{"trials":891,"activeCount":83},[],{"trials":893,"activeCount":83},[],{"trials":895,"activeCount":83},[],{"trials":897,"activeCount":83},[898],{"nctId":899,"briefTitle":900,"status":91,"phases":901,"primaryCompletion":902,"completion":902,"start":678,"enrollment":83,"conditions":903,"interventions":904},"NCT00760916","FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and\u002For a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)",[73],"2009-01",[18],[888,905,906],"UT-15C 0.25 mg","UT-15C 5 mg",{"trials":908,"activeCount":83},[],{"trials":910,"activeCount":83},[],{"intervention":905,"totalTrials":179,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":83},[],{"trials":916,"activeCount":83},[],{"trials":918,"activeCount":83},[],{"trials":920,"activeCount":83},[921],{"nctId":899,"briefTitle":900,"status":91,"phases":922,"primaryCompletion":902,"completion":902,"start":678,"enrollment":83,"conditions":923,"interventions":924},[73],[18],[888,905,906],{"trials":926,"activeCount":83},[],{"trials":928,"activeCount":83},[],{"intervention":906,"totalTrials":179,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":943,"NA":945},{"trials":932,"activeCount":83},[],{"trials":934,"activeCount":83},[],{"trials":936,"activeCount":83},[],{"trials":938,"activeCount":83},[939],{"nctId":899,"briefTitle":900,"status":91,"phases":940,"primaryCompletion":902,"completion":902,"start":678,"enrollment":83,"conditions":941,"interventions":942},[73],[18],[888,905,906],{"trials":944,"activeCount":83},[],{"trials":946,"activeCount":83},[],{"intervention":948,"totalTrials":179,"cells":949},"Remodulin® (treprostinil sodium)",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":969,"NA":971},{"trials":951,"activeCount":83},[],{"trials":953,"activeCount":83},[],{"trials":955,"activeCount":83},[],{"trials":957,"activeCount":83},[958],{"nctId":959,"briefTitle":960,"status":124,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":490,"conditions":964,"interventions":968},"NCT00060996","Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures",[73],"2004-09","2003-02",[965,492,966,967],"Critical Limb Ischemia","Foot Ulcers","Rest Leg Pain",[948],{"trials":970,"activeCount":83},[],{"trials":972,"activeCount":83},[],{"intervention":974,"totalTrials":179,"cells":975},"Treprostinil Diolamine",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":993,"NA":995},{"trials":977,"activeCount":83},[],{"trials":979,"activeCount":83},[],{"trials":981,"activeCount":83},[],{"trials":983,"activeCount":83},[984],{"nctId":985,"briefTitle":986,"status":102,"phases":987,"primaryCompletion":988,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT01560624","Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy",[73],"2018-06-24","2012-06-26",690,[15],[974],{"trials":994,"activeCount":83},[],{"trials":996,"activeCount":83},[],{"intervention":998,"totalTrials":179,"cells":999},"UT-15",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1016,"NA":1018},{"trials":1001,"activeCount":83},[],{"trials":1003,"activeCount":83},[],{"trials":1005,"activeCount":83},[],{"trials":1007,"activeCount":83},[1008],{"nctId":1009,"briefTitle":1010,"status":102,"phases":1011,"completion":1012,"start":1013,"conditions":1014,"interventions":1015},"NCT00004497","Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension",[73],"2000-09","1998-10",[18],[998],{"trials":1017,"activeCount":83},[],{"trials":1019,"activeCount":83},[],{"intervention":1021,"totalTrials":179,"cells":1022},"Irinotecan",{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1029,"PHASE4":1044,"NA":1046},{"trials":1024,"activeCount":83},[],{"trials":1026,"activeCount":83},[],{"trials":1028,"activeCount":83},[],{"trials":1030,"activeCount":83},[1031],{"nctId":1032,"briefTitle":1033,"status":102,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT03098030","Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer",[72,73],"2020-01-27","2020-03-26","2017-06-01",483,[1040],"Small Cell Lung Cancer",[1042,1021,1043],"Dinutuximab","Topotecan",{"trials":1045,"activeCount":83},[],{"trials":1047,"activeCount":83},[],{"intervention":1043,"totalTrials":179,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":83},[],{"trials":1053,"activeCount":83},[],{"trials":1055,"activeCount":83},[],{"trials":1057,"activeCount":83},[1058],{"nctId":1032,"briefTitle":1033,"status":102,"phases":1059,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1060,"interventions":1061},[72,73],[1040],[1042,1021,1043],{"trials":1063,"activeCount":83},[],{"trials":1065,"activeCount":83},[],{"intervention":746,"totalTrials":179,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":83},[],{"trials":1071,"activeCount":83},[],{"trials":1073,"activeCount":83},[1074],{"nctId":739,"briefTitle":740,"status":102,"phases":1075,"primaryCompletion":710,"completion":710,"start":742,"enrollment":743,"conditions":1076,"interventions":1077},[72],[15],[715,746],{"trials":1079,"activeCount":83},[],{"trials":1081,"activeCount":83},[],{"trials":1083,"activeCount":83},[],{"intervention":1085,"totalTrials":179,"cells":1086},"UT-231B",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1088,"activeCount":83},[],{"trials":1090,"activeCount":83},[],{"trials":1092,"activeCount":83},[1093],{"nctId":1094,"briefTitle":1095,"status":1096,"phases":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1103},"NCT00069511","12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.","UNKNOWN",[72],"2004-12","2003-07",72,[1102],"Hepatitis C",[1085],{"trials":1105,"activeCount":83},[],{"trials":1107,"activeCount":83},[],{"trials":1109,"activeCount":83},[],{"intervention":1111,"totalTrials":179,"cells":1112},"ch14.18 -NCI",{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1114,"activeCount":83},[],{"trials":1116,"activeCount":83},[],{"trials":1118,"activeCount":83},[1119],{"nctId":1120,"briefTitle":1121,"status":102,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":679,"conditions":1125,"interventions":1127},"NCT01592045","ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma",[71,72],"2014-06","2012-08",[1126],"Neuroblastoma",[1111,1128,1129,1130,1131],"ch14.18-UTC","Granulocyte-Macrophage Colony-Stimulating Factor","Aldesleukin","Isotretinoin",{"trials":1133,"activeCount":83},[],{"trials":1135,"activeCount":83},[],{"trials":1137,"activeCount":83},[],{"intervention":1128,"totalTrials":179,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":83},[],{"trials":1143,"activeCount":83},[],{"trials":1145,"activeCount":83},[1146],{"nctId":1120,"briefTitle":1121,"status":102,"phases":1147,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":679,"conditions":1148,"interventions":1149},[71,72],[1126],[1111,1128,1129,1130,1131],{"trials":1151,"activeCount":83},[],{"trials":1153,"activeCount":83},[],{"trials":1155,"activeCount":83},[],{"intervention":1129,"totalTrials":179,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1159,"activeCount":83},[],{"trials":1161,"activeCount":83},[],{"trials":1163,"activeCount":83},[1164],{"nctId":1120,"briefTitle":1121,"status":102,"phases":1165,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":679,"conditions":1166,"interventions":1167},[71,72],[1126],[1111,1128,1129,1130,1131],{"trials":1169,"activeCount":83},[],{"trials":1171,"activeCount":83},[],{"trials":1173,"activeCount":83},[],{"intervention":1130,"totalTrials":179,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":83},[],{"trials":1179,"activeCount":83},[],{"trials":1181,"activeCount":83},[1182],{"nctId":1120,"briefTitle":1121,"status":102,"phases":1183,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":679,"conditions":1184,"interventions":1185},[71,72],[1126],[1111,1128,1129,1130,1131],{"trials":1187,"activeCount":83},[],{"trials":1189,"activeCount":83},[],{"trials":1191,"activeCount":83},[],{"intervention":1131,"totalTrials":179,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1195,"activeCount":83},[],{"trials":1197,"activeCount":83},[],{"trials":1199,"activeCount":83},[1200],{"nctId":1120,"briefTitle":1121,"status":102,"phases":1201,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":679,"conditions":1202,"interventions":1203},[71,72],[1126],[1111,1128,1129,1130,1131],{"trials":1205,"activeCount":83},[],{"trials":1207,"activeCount":83},[],{"trials":1209,"activeCount":83},[],{"intervention":1211,"totalTrials":179,"cells":1212},"MAb-3F8",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1214,"activeCount":83},[],{"trials":1216,"activeCount":83},[],{"trials":1218,"activeCount":83},[1219],{"nctId":1220,"briefTitle":1221,"status":124,"phases":1222,"primaryCompletion":648,"start":1223,"enrollment":179,"conditions":1224,"interventions":1226},"NCT00969722","A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients",[72],"2009-08",[1225],"Primary Refractory Neuroblastoma",[1211,1227,1228],"Subcutaneous Granulocyte Macrophage Colony Stimulating Factor","13-cis-Retinoic Acid",{"trials":1230,"activeCount":83},[],{"trials":1232,"activeCount":83},[],{"trials":1234,"activeCount":83},[],{"intervention":1227,"totalTrials":179,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":83},[],{"trials":1240,"activeCount":83},[],{"trials":1242,"activeCount":83},[1243],{"nctId":1220,"briefTitle":1221,"status":124,"phases":1244,"primaryCompletion":648,"start":1223,"enrollment":179,"conditions":1245,"interventions":1246},[72],[1225],[1211,1227,1228],{"trials":1248,"activeCount":83},[],{"trials":1250,"activeCount":83},[],{"trials":1252,"activeCount":83},[],{"intervention":1228,"totalTrials":179,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":83},[],{"trials":1258,"activeCount":83},[],{"trials":1260,"activeCount":83},[1261],{"nctId":1220,"briefTitle":1221,"status":124,"phases":1262,"primaryCompletion":648,"start":1223,"enrollment":179,"conditions":1263,"interventions":1264},[72],[1225],[1211,1227,1228],{"trials":1266,"activeCount":83},[],{"trials":1268,"activeCount":83},[],{"trials":1270,"activeCount":83},[],{"intervention":1272,"totalTrials":179,"cells":1273},"APD811",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1275,"activeCount":83},[],{"trials":1277,"activeCount":83},[],{"trials":1279,"activeCount":83},[1280],{"nctId":1281,"briefTitle":1282,"status":102,"phases":1283,"primaryCompletion":147,"completion":147,"start":752,"enrollment":1284,"conditions":1285,"interventions":1286},"NCT02279160","Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension",[72],61,[15],[1272],{"trials":1288,"activeCount":83},[],{"trials":1290,"activeCount":83},[],{"trials":1292,"activeCount":83},[],{"intervention":118,"totalTrials":179,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":83},[],{"trials":1298,"activeCount":83},[],{"trials":1300,"activeCount":83},[1301],{"nctId":111,"briefTitle":112,"status":91,"phases":1302,"primaryCompletion":114,"completion":114,"start":115,"enrollment":83,"conditions":1303,"interventions":1304},[72],[15],[118,78],{"trials":1306,"activeCount":83},[],{"trials":1308,"activeCount":83},[],{"trials":1310,"activeCount":83},[],{"intervention":1312,"totalTrials":179,"cells":1313},"IV Remodulin",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1315,"activeCount":83},[],{"trials":1317,"activeCount":83},[],{"trials":1319,"activeCount":83},[1320],{"nctId":1321,"briefTitle":1322,"status":124,"phases":1323,"primaryCompletion":1324,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1330},"NCT02261883","Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn",[72],"2022-09-27","2023-05-17","2015-07-29",42,[1329],"Persistent Pulmonary Hypertension of the Newborn",[1312],{"trials":1332,"activeCount":83},[],{"trials":1334,"activeCount":83},[],{"trials":1336,"activeCount":83},[],{"intervention":643,"totalTrials":179,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1340,"activeCount":83},[],{"trials":1342,"activeCount":83},[1343],{"nctId":635,"briefTitle":636,"status":102,"phases":1344,"primaryCompletion":638,"completion":638,"start":639,"enrollment":490,"conditions":1345,"interventions":1346},[71],[23,15],[642,643],{"trials":1348,"activeCount":83},[],{"trials":1350,"activeCount":83},[],{"trials":1352,"activeCount":83},[],{"trials":1354,"activeCount":83},[],{"intervention":1356,"totalTrials":179,"cells":1357},"PLX-PAD",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1359,"activeCount":83},[],{"trials":1361,"activeCount":83},[1362],{"nctId":1363,"briefTitle":1364,"status":124,"phases":1365,"primaryCompletion":240,"completion":1366,"start":1367,"enrollment":11,"conditions":1368,"interventions":1369},"NCT01795950","Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)",[71],"2016-01","2013-04",[15],[1356],{"trials":1371,"activeCount":83},[],{"trials":1373,"activeCount":83},[],{"trials":1375,"activeCount":83},[],{"trials":1377,"activeCount":83},[],{"intervention":1379,"totalTrials":179,"cells":1380},"TransCon PEG treprostinil",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1392,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1382,"activeCount":83},[],{"trials":1384,"activeCount":83},[1385],{"nctId":1386,"briefTitle":1387,"status":91,"phases":1388,"primaryCompletion":1389,"start":751,"enrollment":83,"conditions":1390,"interventions":1391},"NCT02149095","Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers",[71],"2014-11",[26],[1379],{"trials":1393,"activeCount":83},[],{"trials":1395,"activeCount":83},[],{"trials":1397,"activeCount":83},[],{"trials":1399,"activeCount":83},[],{"intervention":1401,"totalTrials":179,"cells":1402},"Treprostinil Inhalation Powder",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1404,"activeCount":83},[],{"trials":1406,"activeCount":83},[1407],{"nctId":1408,"briefTitle":1409,"status":102,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1415},"NCT03950739","Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso",[71],"2023-08-22","2019-09-17",51,[15],[1401],{"trials":1417,"activeCount":83},[],{"trials":1419,"activeCount":83},[],{"trials":1421,"activeCount":83},[],{"trials":1423,"activeCount":83},[],{"intervention":1425,"totalTrials":179,"cells":1426},"UNEX-42",{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1441,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1428,"activeCount":83},[],{"trials":1430,"activeCount":83},[1431],{"nctId":1432,"briefTitle":1433,"status":124,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":12,"conditions":1437,"interventions":1439},"NCT03857841","A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD",[71],"2021-05-20","2019-10-09",[1438],"Bronchopulmonary Dysplasia",[1425,1440],"Phosphate-buffered saline",{"trials":1442,"activeCount":83},[],{"trials":1444,"activeCount":83},[],{"trials":1446,"activeCount":83},[],{"trials":1448,"activeCount":83},[],{"intervention":1440,"totalTrials":179,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1452,"activeCount":83},[],{"trials":1454,"activeCount":83},[1455],{"nctId":1432,"briefTitle":1433,"status":124,"phases":1456,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":12,"conditions":1457,"interventions":1458},[71],[1438],[1425,1440],{"trials":1460,"activeCount":83},[],{"trials":1462,"activeCount":83},[],{"trials":1464,"activeCount":83},[],{"trials":1466,"activeCount":83},[],{"intervention":1468,"totalTrials":12,"cells":1469},"Treprostinil",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1488},{"trials":1471,"activeCount":83},[],{"trials":1473,"activeCount":83},[],{"trials":1475,"activeCount":83},[],{"trials":1477,"activeCount":83},[],{"trials":1479,"activeCount":83},[1480],{"nctId":1481,"briefTitle":1482,"status":124,"phases":1483,"primaryCompletion":639,"completion":697,"start":1484,"enrollment":8,"conditions":1485,"interventions":1486},"NCT00439946","Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH",[74],"2007-02",[15],[1487],"treprostinil",{"trials":1489,"activeCount":83},[1490,1500],{"nctId":1491,"briefTitle":1492,"status":102,"phases":1493,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":1497,"interventions":1498},"NCT03888365","Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH",[],"2019-09-19","2019-04-01",43,[15],[1468,1499],"Non-Treprostinil PAH Medications",{"nctId":1501,"briefTitle":1502,"status":102,"phases":1503,"primaryCompletion":1367,"completion":1367,"start":1504,"enrollment":712,"conditions":1505,"interventions":1507},"NCT01028651","A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension",[],"2011-01",[1506,15,18],"Portopulmonary Hypertension",[1468],{"intervention":1042,"totalTrials":306,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1522,"NA":1524},{"trials":1511,"activeCount":83},[],{"trials":1513,"activeCount":83},[],{"trials":1515,"activeCount":83},[],{"trials":1517,"activeCount":83},[1518],{"nctId":1032,"briefTitle":1033,"status":102,"phases":1519,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1520,"interventions":1521},[72,73],[1040],[1042,1021,1043],{"trials":1523,"activeCount":83},[],{"trials":1525,"activeCount":83},[1526],{"nctId":1527,"briefTitle":1528,"status":124,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":712,"conditions":1532,"interventions":1533},"NCT02693171","Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients",[],"2016-12-19","2016-03-15",[1126],[1042],{"intervention":1535,"totalTrials":179,"cells":1536},"inhaled prostacyclin",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1538,"activeCount":83},[],{"trials":1540,"activeCount":83},[],{"trials":1542,"activeCount":83},[],{"trials":1544,"activeCount":83},[],{"trials":1546,"activeCount":83},[],{"trials":1548,"activeCount":83},[1549],{"nctId":1550,"briefTitle":1551,"status":102,"phases":1552,"primaryCompletion":752,"completion":752,"start":314,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT01266265","Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies",[],1333,[15],[1535,1535,1556,1557,1558,1559],"prostacyclin","subcutaneous and intravenous prostacyclin","oral ERA","oral PDE5 inhibitors",{"intervention":1556,"totalTrials":179,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1563,"activeCount":83},[],{"trials":1565,"activeCount":83},[],{"trials":1567,"activeCount":83},[],{"trials":1569,"activeCount":83},[],{"trials":1571,"activeCount":83},[],{"trials":1573,"activeCount":83},[1574],{"nctId":1550,"briefTitle":1551,"status":102,"phases":1575,"primaryCompletion":752,"completion":752,"start":314,"enrollment":1553,"conditions":1576,"interventions":1577},[],[15],[1535,1535,1556,1557,1558,1559],{"intervention":1557,"totalTrials":179,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1581,"activeCount":83},[],{"trials":1583,"activeCount":83},[],{"trials":1585,"activeCount":83},[],{"trials":1587,"activeCount":83},[],{"trials":1589,"activeCount":83},[],{"trials":1591,"activeCount":83},[1592],{"nctId":1550,"briefTitle":1551,"status":102,"phases":1593,"primaryCompletion":752,"completion":752,"start":314,"enrollment":1553,"conditions":1594,"interventions":1595},[],[15],[1535,1535,1556,1557,1558,1559],{"intervention":1558,"totalTrials":179,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1599,"activeCount":83},[],{"trials":1601,"activeCount":83},[],{"trials":1603,"activeCount":83},[],{"trials":1605,"activeCount":83},[],{"trials":1607,"activeCount":83},[],{"trials":1609,"activeCount":83},[1610],{"nctId":1550,"briefTitle":1551,"status":102,"phases":1611,"primaryCompletion":752,"completion":752,"start":314,"enrollment":1553,"conditions":1612,"interventions":1613},[],[15],[1535,1535,1556,1557,1558,1559],{"intervention":1559,"totalTrials":179,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1617,"activeCount":83},[],{"trials":1619,"activeCount":83},[],{"trials":1621,"activeCount":83},[],{"trials":1623,"activeCount":83},[],{"trials":1625,"activeCount":83},[],{"trials":1627,"activeCount":83},[1628],{"nctId":1550,"briefTitle":1551,"status":102,"phases":1629,"primaryCompletion":752,"completion":752,"start":314,"enrollment":1553,"conditions":1630,"interventions":1631},[],[15],[1535,1535,1556,1557,1558,1559],{"intervention":1633,"totalTrials":179,"cells":1634},"Remunity Pump for Remodulin",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1636,"activeCount":83},[],{"trials":1638,"activeCount":83},[],{"trials":1640,"activeCount":83},[],{"trials":1642,"activeCount":83},[],{"trials":1644,"activeCount":83},[],{"trials":1646,"activeCount":83},[1647],{"nctId":1648,"briefTitle":1649,"status":124,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":628,"conditions":1653,"interventions":1654},"NCT05060315","Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin",[],"2024-12-31","2023-07-05",[15],[1633],{"intervention":1499,"totalTrials":179,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1658,"activeCount":83},[],{"trials":1660,"activeCount":83},[],{"trials":1662,"activeCount":83},[],{"trials":1664,"activeCount":83},[],{"trials":1666,"activeCount":83},[],{"trials":1668,"activeCount":83},[1669],{"nctId":1491,"briefTitle":1492,"status":102,"phases":1670,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":1671,"interventions":1672},[],[15],[1468,1499]]